Phase 1b Study of ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 May 2019
Price : $35 *
At a glance
- Drugs Apalutamide (Primary) ; Everolimus (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- 01 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 01 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 31 Aug 2018 Biomarkers information updated